Lotus Eye Hospital and Institute share news, announcements and annual reports
NSE: LOTUSEYEBSE: 532998Healthcare ServicesSmall Cap
Lotus Eye Hospital and Institute Limited · Formerly Lotus Eye Care Hospital · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2008
Last close ₹109.15down ₹0.85 (0.77%)BSE ₹106.50
Share price at the NSE close on 30 Oct 2026. Previous close ₹110.00.
30 Oct: open ₹110.01, high ₹110.01, low ₹108.10
52-week range of traded prices to 30 Oct 2026
₹97.59Low, 30 Mar 2026₹147.00High, 30 Jan 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹227 Cr2,287th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 1,520.37
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.77
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 0.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 0.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 17,74995.6% delivered
Lotus Eye Hospital and Institute share news and announcements
455 announcements, routine notices left out, newest first. Page 6 of 10.
Jul 2020
30 Jul · Board meeting
21 Jul · Board meeting
Jun 2020
22 Jun · Legal
The exchange asked on 18 Jun 2020
19 Jun · Board meeting
Not held on this date
Apr 2020
Feb 2020
10 Feb · Legal
Exchange has sought clarification from Lotus Eye Hospital and Institute Limited for the quarter ended 31-Dec-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. No Segment Reporting. The response of the Company is awaited.6 Feb · Results
6 Feb · Board meeting
Jan 2020
25 Jan · Board meeting
16 Jan · Legal
Exchange has sought clarification from Lotus Eye Hospital and Institute Limited with respect to announcement dated 13-Jan-2020, regarding Board meeting held on January 13, 2020.On basis of above the Company is required to clarify following: 1. Brief profile and Date of appointment & term of appointment in case of appointment of Dr. S. Rajkumar. The response of the Company is awaited.13 Jan · Board meeting
Nov 2019
19 Nov · Legal
Exchange has sought clarification from Lotus Eye Hospital and Institute Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.15 Nov · Corrigendum
14 Nov · Results
14 Nov · Board meeting
Oct 2019
30 Oct · Board meeting
Sep 2019
10 Sep · Corrigendum
Aug 2019
14 Aug · Legal
Exchange has sought clarification from Lotus Eye Hospital and Institute Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. No Segment Reporting. The response of the Company is awaited.12 Aug · Results
12 Aug · Board meeting
Jul 2019
29 Jul · Monthly Business Updates
Jun 2019
3 Jun · Legal
Exchange has sought clarification from Lotus Eye Hospital and Institute Limited with respect to 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. No Segment Reporting. The response of the Company is awaited.
May 2019
28 May · Results
28 May · Board meeting
Apr 2019
Feb 2019
6 Feb · Legal
Exchange has sought clarification from Lotus Eye Hospital and Institute Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies -2. No Segment Reporting. The response of the Company is awaited.5 Feb · Board meeting
5 Feb · Results
Jan 2019
17 Jan · Board meeting
Nov 2018
12 Nov · Results
12 Nov · Board meeting
Oct 2018